What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2024-02-20 compared with 2023-02-17 · 39 added, 40 removed, 48 unchanged (62% of the section changed)

5 unchanged sentences

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The following table lists AbbVie's executive officers:

Name Age Position

Gonzalez 70 Chairman of the Board and Chief Executive Officer

Michael 52 Vice Chairman and President

Michael 53 President and Chief Operating Officer

Reents 56 Executive Vice President, Chief Financial Officer

Donoghoe, M.D.

43 Executive Vice President, Chief Business and Strategy Officer

Richmond 57 Executive Vice President, Chief Human Resources Officer

Azita Saleki-Gerhardt, Ph.D.

59 Executive Vice President, Operations

60 Executive Vice President, Chief Operations Officer

Siatis 49 Executive Vice President, General Counsel and Secretary

Stewart 55 Executive Vice President, Chief Commercial Officer

61 Senior Vice President, Research & Development and Chief Scientific Officer

Sorg 56 Senior Vice President, AbbVie and President, U.S.

Commercial Operations

Carrie Strom 45 Senior Vice President, AbbVie and President, Global Allergan Aesthetics

Durkin 62 Vice President, Controller

58 Senior Vice President, Controller

62 Senior Vice President, Chief Scientific Officer, Global Research

Roopal Thakkar, M.D.

52 Senior Vice President, Chief Medical Officer, Global Therapeutics

_______________________________________________________________________________

Gonzalez is the Chairman and Chief Executive Officer of AbbVie.

Gonzalez is the Chairman and Chief Executive Officer of AbbVie, a position he has held since 2013.

He served as Abbott’s Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott’s worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing.

He also served as President, Abbott Ventures Inc., Abbott’s medical technology investment arm, from 2009 to 2011.

Gonzalez joined Abbott in 1977 and held various management positions.

He was first appointed as an AbbVie corporate officer in December 2012.

Michael is AbbVie’s Vice Chairman and President.

Michael previously served as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018.

He served as AbbVie’s Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and Vice President, Financial Planning and Analysis from 2012 to 2013.

Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including:

Abbott’s President and Chief Operating Officer; President, Chief Operating Officer of Abbott’s Medical Products Group; Senior Vice President and President of Abbott’s former Hospital Products Division; Vice President and President of Abbott’s Health Systems Division; and Divisional Vice President and General Manager for Abbott’s Diagnostics Operations in the United States and Canada.

On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr.

Michael to succeed Mr.

Gonzalez as the Company's Chief Executive Officer.

Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.

Michael is AbbVie’s President and Chief Operating Officer.

Michael previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018.

He served as AbbVie’s Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013.

At Abbott, Mr.

1 unchanged sentence

Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.

On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr.

Michael to succeed Mr.

Gonzalez as the Company's Chief Executive Officer.

Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.

The Board also appointed Mr.

Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.

Reents is AbbVie’s Executive Vice President, Chief Financial Officer.

1 unchanged sentence

Reents joined Abbott in 2008 and was first appointed as an AbbVie corporate officer in June 2022.

Donoghoe is AbbVie’s Executive Vice President, Chief Business and Strategy Officer.

He has previously served as AbbVie’s Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020.

Prior to joining AbbVie in 2019, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.

Richmond is AbbVie’s Executive Vice President, Chief Human Resources Officer.

2 unchanged sentences

Richmond joined Abbott in 2006 and was first appointed as an AbbVie corporate officer in December 2012.

Saleki-Gerhardt is AbbVie’s Executive Vice President, Operations.

She served as Senior Vice President, Operations from 2013 to 2018.

2023 Form 10-K |

Saleki-Gerhardt is AbbVie’s Executive Vice President, Chief Operations Officer.

She served as Executive Vice President, Operations from 2018 to July 2023, and as Senior Vice President, Operations from 2013 to 2018.

Saleki-Gerhardt served as Abbott’s Vice President, Pharmaceuticals Manufacturing and Supply from 2011 to 2012, and as Divisional Vice President, Quality Assurance, Global Pharmaceutical Operations from 2008 to 2011.

4 unchanged sentences

From 2013 until 2021, Mr.

Siatis also served in various roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer;

Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer;

and Vice President, Biologic Strategic Development and Legal Regulatory.

Siatis also served in various roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer; Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer; and Vice President, Biologic Strategic Development and Legal Regulatory.

Siatis joined Abbott in 2005 and was first appointed as an AbbVie corporate officer in October 2022.

2 unchanged sentences

Commercial Operations from 2018 to 2020 and as AbbVie’s President, Commercial Operations from 2013 to 2018.

| 2022 Form 10-K

Prior to AbbVie’s separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States.

Stewart joined Abbott in 1992 and was first appointed as an AbbVie corporate officer in December 2018.

Hudson is AbbVie's Senior Vice President, Research & Development and Chief Scientific Officer.

He previously served as Vice President, Head of Oncology Discovery and Early Development from 2016 to 2019.

Buckbee is AbbVie’s Senior Vice President, Controller.

Buckbee previously served as AbbVie’s Vice President, Controller, Global Commercial Operations from January 2016 until March 2023, and as Vice President, Controller, US Commercial Operations from AbbVie’s separation from Abbott in 2013 until December 2015.

Buckbee joined Abbott in 1991 and held several positions in the finance organization.

Hudson is AbbVie's Senior Vice President, Chief Scientific Officer, Global Research.

He previously served as Senior Vice President, Research & Development and Chief Scientific Officer from 2019 to 2023, and as Vice President, Head of Oncology Discovery and Early Development from 2016 to 2019.

Prior to joining AbbVie, Dr.

2 unchanged sentences

Hudson was first appointed as an AbbVie corporate officer in July 2019.

Sorg is AbbVie’s Senior Vice President, AbbVie, and President U.S.

Commercial Operations.

She previously served as AbbVie’s President, U.S.

Immunology and Patient Services from 2019 to 2020 and as Vice President, Immunology and Oncology from 2016 to 2018.

She served as Vice President, Immunology prior to AbbVie’s separation from Abbott and until 2016 at AbbVie.

Sorg joined Abbott in 2012 and was first appointed as an AbbVie corporate officer in November 2020.

Prior to joining Abbott, Ms.

Sorg served in management roles at Eli Lilly and Company for 23 years.

Strom is AbbVie’s Senior Vice President, AbbVie, and President, Global Allergan Aesthetics, responsible for the worldwide operations of the aesthetics franchise.

She was appointed to the position upon AbbVie’s acquisition of Allergan in 2020 and was first appointed as an AbbVie corporate officer in May 2020.

At Allergan, Ms.

Strom previously served as Senior Vice President, U.S.

Medical Aesthetics from 2018 to 2020.

She joined Allergan in 2011.

Durkin is AbbVie’s Vice President, Controller.

Durkin previously served as Vice President, Internal Audit from 2016 to 2018.

Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbott’s Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009.

Durkin joined Abbott in 1986 and was first appointed as an AbbVie corporate officer in October 2018.

Thakkar serves as AbbVie's Senior Vice President, Chief Medical Officer, Global Therapeutics.

He previously served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from late 2022 until early December 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019.

Thakkar joined Abbott in 2003 and was first appointed as a corporate officer in December 2023.

The executive officers of AbbVie are elected annually by the board of directors.

5 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings